17,216 argenex SE $ARGX Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC cut its holdings in shares of argenex SE (NASDAQ:ARGX – Free Report) by 6.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 247,401 shares of the company’s stock after selling 17,216 shares during the period. argenex comprises approximately 0.8% of William Blair Investment Management LLC’s holdings, making the stock its 25th largest holding. William Blair Investment Management LLC owned approximately 0.39% of argenex worth $237,204,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Eastern Bank acquired a new stake in argenex during the 2nd quarter valued at $32,000. Axiom Investment Management LLC bought a new position in argenex in the 1st quarter valued at $50,000. Richardson Financial Services Inc. acquired a new position in argenex in the third quarter worth $66,000. Mather Group LLC. boosted its stake in argenex by 19.1% in the third quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after purchasing an additional 13 shares in the last quarter. Finally, Provenance Wealth Advisors LLC acquired a new position in argenex in the third quarter worth $84,000. 60.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ARGX has been the topic of several research analyst reports. Morgan Stanley decreased their target price on argenex from $1,190.00 to $1,130.00 and set an “overweight” rating on the stock in a report on Friday. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of argenex in a report on Wednesday, August 5th. Sanford C. Bernstein reiterated a “buy” rating on shares of argenex in a research report on Thursday, October 8th. Jefferies Financial Group reiterated a “buy” rating on shares of argenex in a research report on Monday, September 14th. Finally, DZ Bank reissued a “buy” rating on shares of argenex in a report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and a consensus target price of $1,163.18.

Check Out Our Latest Analysis on ARGX

argenex Price Performance

Shares of ARGX opened at $960.04 on Monday. The stock’s fifty day simple moving average is $923.87 and its 200-day simple moving average is $860.78. The firm has a market capitalization of $60.38 billion, a PE ratio of 33.50, a price-to-earnings-growth ratio of 0.89 and a beta of 0.48. argenex SE has a 12-month low of $661.85 and a 12-month high of $1,072.75.

argenex (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. The firm had revenue of $1.75 billion during the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. Analysts anticipate that argenex SE will post 28.41 EPS for the current year.

About argenex

(Free Report)

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

Featured Articles

Institutional Ownership by Quarter for argenex (NASDAQ:ARGX)

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.